Cargando…
Disease-specific ACMG/AMP guidelines improve sequence variant interpretation for hearing loss
PURPOSE: The ClinGen Variant Curation Expert Panels (VCEPs) provide disease-specific rules for accurate variant interpretation. Using the hearing loss-specific ACMG/AMP guidelines, the Hearing Loss VCEP (HL VCEP) illustrates the utility of expert specifications in variant interpretation. METHODS: A...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556313/ https://www.ncbi.nlm.nih.gov/pubmed/34230634 http://dx.doi.org/10.1038/s41436-021-01254-2 |
_version_ | 1784592154093420544 |
---|---|
author | Patel, Mayher J DiStefano, Marina T Oza, Andrea M Hughes, Madeline Y Wilcox, Emma H Hemphill, Sarah E Cushman, Brandon J Grant, Andrew R Siegert, Rebecca K Shen, Jun Chapin, Alex Boczek, Nicole J Schimmenti, Lisa A Nara, Kiyomitsu Kenna, Margaret Azaiez, Hela Booth, Kevin T Avraham, Karen B Kremer, Hannie Griffith, Andrew J. Rehm, Heidi L Amr, Sami S Tayoun, Ahmad N Abou |
author_facet | Patel, Mayher J DiStefano, Marina T Oza, Andrea M Hughes, Madeline Y Wilcox, Emma H Hemphill, Sarah E Cushman, Brandon J Grant, Andrew R Siegert, Rebecca K Shen, Jun Chapin, Alex Boczek, Nicole J Schimmenti, Lisa A Nara, Kiyomitsu Kenna, Margaret Azaiez, Hela Booth, Kevin T Avraham, Karen B Kremer, Hannie Griffith, Andrew J. Rehm, Heidi L Amr, Sami S Tayoun, Ahmad N Abou |
author_sort | Patel, Mayher J |
collection | PubMed |
description | PURPOSE: The ClinGen Variant Curation Expert Panels (VCEPs) provide disease-specific rules for accurate variant interpretation. Using the hearing loss-specific ACMG/AMP guidelines, the Hearing Loss VCEP (HL VCEP) illustrates the utility of expert specifications in variant interpretation. METHODS: A total of 157 variants across nine HL genes, previously submitted to ClinVar, were curated by the HL VCEP. The curation process involved collecting published and unpublished data for each variant by biocurators, followed by bi-monthly meetings of an expert curation subgroup that reviewed all evidence and applied the HL-specific ACMG/AMP guidelines to reach a final classification. RESULTS: Before expert curation, 75% (117/157) of variants had single or multiple VUS submissions (17/157) or had conflicting interpretations in ClinVar (100/157). After applying the HL-specific ACMG/AMP guidelines, 24% (4/17) of VUS and 69% (69/100) of discordant variants were resolved into Benign (B), Likely Benign (LB), Likely Pathogenic (LP), or Pathogenic (P). Overall, 70% (109/157) variants had unambiguous classifications (B, LB, LP, P). We quantify the contribution of the HL-specified ACMG/AMP codes to variant classification. CONCLUSION: Expert specification and application of the HL-specific ACMG/AMP guidelines effectively resolved discordant interpretations in ClinVar. This study highlights the utility of ClinGen VCEPs in supporting more consistent clinical variant interpretation. |
format | Online Article Text |
id | pubmed-8556313 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
record_format | MEDLINE/PubMed |
spelling | pubmed-85563132022-01-06 Disease-specific ACMG/AMP guidelines improve sequence variant interpretation for hearing loss Patel, Mayher J DiStefano, Marina T Oza, Andrea M Hughes, Madeline Y Wilcox, Emma H Hemphill, Sarah E Cushman, Brandon J Grant, Andrew R Siegert, Rebecca K Shen, Jun Chapin, Alex Boczek, Nicole J Schimmenti, Lisa A Nara, Kiyomitsu Kenna, Margaret Azaiez, Hela Booth, Kevin T Avraham, Karen B Kremer, Hannie Griffith, Andrew J. Rehm, Heidi L Amr, Sami S Tayoun, Ahmad N Abou Genet Med Article PURPOSE: The ClinGen Variant Curation Expert Panels (VCEPs) provide disease-specific rules for accurate variant interpretation. Using the hearing loss-specific ACMG/AMP guidelines, the Hearing Loss VCEP (HL VCEP) illustrates the utility of expert specifications in variant interpretation. METHODS: A total of 157 variants across nine HL genes, previously submitted to ClinVar, were curated by the HL VCEP. The curation process involved collecting published and unpublished data for each variant by biocurators, followed by bi-monthly meetings of an expert curation subgroup that reviewed all evidence and applied the HL-specific ACMG/AMP guidelines to reach a final classification. RESULTS: Before expert curation, 75% (117/157) of variants had single or multiple VUS submissions (17/157) or had conflicting interpretations in ClinVar (100/157). After applying the HL-specific ACMG/AMP guidelines, 24% (4/17) of VUS and 69% (69/100) of discordant variants were resolved into Benign (B), Likely Benign (LB), Likely Pathogenic (LP), or Pathogenic (P). Overall, 70% (109/157) variants had unambiguous classifications (B, LB, LP, P). We quantify the contribution of the HL-specified ACMG/AMP codes to variant classification. CONCLUSION: Expert specification and application of the HL-specific ACMG/AMP guidelines effectively resolved discordant interpretations in ClinVar. This study highlights the utility of ClinGen VCEPs in supporting more consistent clinical variant interpretation. 2021-07-06 2021-11 /pmc/articles/PMC8556313/ /pubmed/34230634 http://dx.doi.org/10.1038/s41436-021-01254-2 Text en http://www.nature.com/authors/editorial_policies/license.html#termsUsers may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Patel, Mayher J DiStefano, Marina T Oza, Andrea M Hughes, Madeline Y Wilcox, Emma H Hemphill, Sarah E Cushman, Brandon J Grant, Andrew R Siegert, Rebecca K Shen, Jun Chapin, Alex Boczek, Nicole J Schimmenti, Lisa A Nara, Kiyomitsu Kenna, Margaret Azaiez, Hela Booth, Kevin T Avraham, Karen B Kremer, Hannie Griffith, Andrew J. Rehm, Heidi L Amr, Sami S Tayoun, Ahmad N Abou Disease-specific ACMG/AMP guidelines improve sequence variant interpretation for hearing loss |
title | Disease-specific ACMG/AMP guidelines improve sequence variant interpretation for hearing loss |
title_full | Disease-specific ACMG/AMP guidelines improve sequence variant interpretation for hearing loss |
title_fullStr | Disease-specific ACMG/AMP guidelines improve sequence variant interpretation for hearing loss |
title_full_unstemmed | Disease-specific ACMG/AMP guidelines improve sequence variant interpretation for hearing loss |
title_short | Disease-specific ACMG/AMP guidelines improve sequence variant interpretation for hearing loss |
title_sort | disease-specific acmg/amp guidelines improve sequence variant interpretation for hearing loss |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556313/ https://www.ncbi.nlm.nih.gov/pubmed/34230634 http://dx.doi.org/10.1038/s41436-021-01254-2 |
work_keys_str_mv | AT patelmayherj diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT distefanomarinat diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT ozaandream diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT hughesmadeliney diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT wilcoxemmah diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT hemphillsarahe diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT cushmanbrandonj diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT grantandrewr diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT siegertrebeccak diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT shenjun diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT chapinalex diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT boczeknicolej diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT schimmentilisaa diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT narakiyomitsu diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT kennamargaret diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT azaiezhela diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT boothkevint diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT avrahamkarenb diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT kremerhannie diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT griffithandrewj diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT rehmheidil diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT amrsamis diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT tayounahmadnabou diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss AT diseasespecificacmgampguidelinesimprovesequencevariantinterpretationforhearingloss |